Advertisement

Advertisement
Skin Cancer

Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma

In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting and in The New England Journal of Medicine...

Issues in Oncology
Cost of Care

Major Settlement Raises Questions About Evidence-Based Value in Cancer Care

An Oklahoma jury recently awarded $25.5 million to the widower of a 53-year-old woman diagnosed with stage IV nasopharyngeal cancer who was denied coverage...

Breast Cancer

New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer

New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years of age or younger has emerged from...


Advertisement
Sarcoma
Immunotherapy

Addition of a Tyrosine Kinase Inhibitor to Immunotherapy in Advanced Sarcomas

In a phase II trial reported in The Lancet OncologyBreelyn Wilky, MD, and colleagues found evidence of activity of axitinib plus pembrolizumab in advanced sarcomas...

Lung Cancer
Immunotherapy

Addition of Bevacizumab to Erlotinib Improves Progression-Free Survival in EGFR-Mutated, Nonsquamous NSCLC

In an interim analysis of the phase III NEJ026 trial reported in The Lancet OncologyMakoto Maemondo, MD, and colleagues found that the addition of bevacizumab...

Advertisement




More Top Stories

Kidney Cancer
Immunotherapy

Ziad Bakouny, MD, and Toni K. Choueiri, MD, on Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease

Breast Cancer

MONALEESA-7 Shows Overall Survival Benefit for Ribociclib/Endocrine Therapy

The first statistically significant overall survival benefit has been shown for a cyclin-dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy as first-line treatment of advanced breast cancer. The results are from the phase III MONALEESA-7 trial, which evaluated ribociclib plus endocrine...

Advertisement

2019 ASCO: Paclitaxel/Carboplatin vs Paclitaxel/Ifosfamide in Carcinosarcoma of the Uterus or Ovary

Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin to paclitaxel plus ifosfamide in women with stage I–IV recurrent carcinosarcoma of the uterus or ovary found that treatment with paclitaxel/carboplatin was not inferior to...

Kidney Cancer
Immunotherapy

Ziad Bakouny, MD, and Toni K. Choueiri, MD, on Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease

New: ASCO Answers Fact Sheet on Fertility and Cancer Treatment for Your Patients

Cancer and cancer treatment can cause infertility in both men and women. Prepare your patients for this possibility by giving them the ASCO Answers fact sheet titled Your Fertility and Cancer Treatment. This fact sheet covers: An overview of what fertility and infertility mean Which cancer...

New Data on Improving Access to Cancer Care, Advances in Precision Medicine Highlighted at 2019 ASCO Annual Meeting

As this special edition of The ASCO Post goes to press, more than 32,000 cancer experts from around the world have convened in Chicago to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in...

2019 ASCO: OPTiM Study on T-VEC for Unresectable Melanoma

New research on the immunotherapy talimogene laherparepvec (T-VEC)—an injectable oncolytic virus—for patients with unresectable melanoma was presented by Milhem et al at the 2019 ASCO Annual Meeting (Abstract 9524). Researchers reported the ad hoc analysis of progression-free survival...

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

ASCO Honors Leaders in Cancer Care With 2019 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...

Advertisement

2019 ASCO: Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma

In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting (Abstract 9507) and in The New England Journal of Medicine, Robert et al found a 5-year overall survival rate of 34% with the combination of dabrafenib and trametinib in previously untreated...